News AstraZeneca raises guidance on stellar cancer drugs growth AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.
News Leqembi starts to deliver for Eisai and Biogen Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.
News Lilly says 2026 looks good, as sales rocket in Q4 Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.
News GSK delivers in new CEO Miels' first financial update Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits.
News Novo Nordisk slumps on tougher 2026 financial outlook Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.
News Patent losses hit Novartis hard, but CEO has a plan Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
